[go: up one dir, main page]

EA201892745A1 - Фосфорамидатные производные нуклеозида в качестве противораковых агентов - Google Patents

Фосфорамидатные производные нуклеозида в качестве противораковых агентов

Info

Publication number
EA201892745A1
EA201892745A1 EA201892745A EA201892745A EA201892745A1 EA 201892745 A1 EA201892745 A1 EA 201892745A1 EA 201892745 A EA201892745 A EA 201892745A EA 201892745 A EA201892745 A EA 201892745A EA 201892745 A1 EA201892745 A1 EA 201892745A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nucleoside
derivatives
treatment agents
phosphoramidate derivatives
cladribine
Prior art date
Application number
EA201892745A
Other languages
English (en)
Other versions
EA036409B1 (ru
Inventor
Хью Гриффит
Микаэла Серпи
Магдалена Слюсарчик
Original Assignee
НУКАНА ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by НУКАНА ПиЭлСи filed Critical НУКАНА ПиЭлСи
Publication of EA201892745A1 publication Critical patent/EA201892745A1/ru
Publication of EA036409B1 publication Critical patent/EA036409B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Настоящее изобретение относится к производным кладрибина. Соединения представляют собой фосфорамидатные производные, в которых фосфорамидатный фрагмент находится по 3'-гидроксильной группе кладрибина. Настоящее изобретение также относится к фармацевтическим составам производных кладрибина и их применению в способах лечения. Соединения являются пригодными в лечении рака.
EA201892745A 2016-06-01 2017-05-31 Фосфорамидатные производные нуклеозида в качестве противораковых агентов EA036409B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1609601.8A GB201609601D0 (en) 2016-06-01 2016-06-01 Phosphoramidate compounds
PCT/GB2017/051549 WO2017207986A1 (en) 2016-06-01 2017-05-31 Phosphoramidate nucleoside derivatives as anticancer agents

Publications (2)

Publication Number Publication Date
EA201892745A1 true EA201892745A1 (ru) 2019-05-31
EA036409B1 EA036409B1 (ru) 2020-11-06

Family

ID=56410850

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892745A EA036409B1 (ru) 2016-06-01 2017-05-31 Фосфорамидатные производные нуклеозида в качестве противораковых агентов

Country Status (26)

Country Link
US (2) US10906929B2 (ru)
EP (1) EP3464309B1 (ru)
JP (2) JP7025351B2 (ru)
KR (1) KR20190015353A (ru)
CN (1) CN109195981A (ru)
AU (1) AU2017273117B2 (ru)
BR (1) BR112018074961A2 (ru)
CA (1) CA3025440A1 (ru)
CL (1) CL2018003404A1 (ru)
DK (1) DK3464309T3 (ru)
EA (1) EA036409B1 (ru)
ES (1) ES2801448T3 (ru)
GB (1) GB201609601D0 (ru)
HR (1) HRP20200983T1 (ru)
HU (1) HUE051335T2 (ru)
IL (1) IL263121B (ru)
MX (1) MX378839B (ru)
MY (1) MY198880A (ru)
PH (1) PH12018502606A1 (ru)
PL (1) PL3464309T3 (ru)
PT (1) PT3464309T (ru)
SA (1) SA518400552B1 (ru)
SG (1) SG11201810018TA (ru)
SI (1) SI3464309T1 (ru)
WO (1) WO2017207986A1 (ru)
ZA (1) ZA201807652B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
IL291927A (en) 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
MD3464271T2 (ro) 2016-05-31 2020-08-31 Kalvista Pharmaceuticals Ltd Derivați de pirazol în calitate de inhibitori ai kaliсreinei plasmatice
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
WO2019172835A1 (en) * 2018-03-09 2019-09-12 Medivir Aktiebolag Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN110845560B (zh) * 2019-11-21 2021-08-24 广东中科药物研究有限公司 苯丙氨酸酰胺化的核苷酸衍生物及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2415368A1 (en) * 2000-07-13 2002-01-31 Yi Jin Synthesis and antiviral evaluation of nucleic acid based (nab) libraries
CA2589935A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
MX2011007364A (es) 2009-01-09 2012-02-28 Univ Cardiff Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US9156874B2 (en) 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
PL3043803T3 (pl) 2013-09-11 2022-11-07 Emory University Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
BR112016011949A8 (pt) 2013-11-27 2020-04-28 Idenix Pharmaceuticals Llc composto, composição farmacêutica, e, uso dos mesmos”
KR20170005492A (ko) * 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
CN110882268A (zh) 2014-06-25 2020-03-17 努卡那有限公司 包括吉西他滨前药的制剂
IL291927A (en) * 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
EP3307734B1 (en) 2015-06-09 2019-11-27 AbbVie Inc. Nuclear receptor modulators (ror) for the treatment of inflammatory and autoimmune diseases
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds

Also Published As

Publication number Publication date
MX2018014859A (es) 2019-03-07
MX378839B (es) 2025-03-11
PL3464309T3 (pl) 2020-10-19
CN109195981A (zh) 2019-01-11
PH12018502606A1 (en) 2019-10-21
KR20190015353A (ko) 2019-02-13
MY198880A (en) 2023-10-02
WO2017207986A1 (en) 2017-12-07
AU2017273117B2 (en) 2021-02-04
SG11201810018TA (en) 2018-12-28
PT3464309T (pt) 2020-06-23
US20190375779A1 (en) 2019-12-12
HRP20200983T1 (hr) 2020-12-11
EP3464309B1 (en) 2020-06-10
JP7025351B2 (ja) 2022-02-24
US10906929B2 (en) 2021-02-02
EA036409B1 (ru) 2020-11-06
SI3464309T1 (sl) 2020-10-30
SA518400552B1 (ar) 2021-12-08
BR112018074961A2 (pt) 2019-03-12
ES2801448T3 (es) 2021-01-11
ZA201807652B (en) 2021-05-26
JP2019517510A (ja) 2019-06-24
CA3025440A1 (en) 2017-12-07
IL263121B (en) 2021-10-31
EP3464309A1 (en) 2019-04-10
DK3464309T3 (da) 2020-06-29
HUE051335T2 (hu) 2021-03-01
GB201609601D0 (en) 2016-07-13
US20210130387A1 (en) 2021-05-06
JP2022051936A (ja) 2022-04-01
AU2017273117A1 (en) 2018-12-06
CL2018003404A1 (es) 2019-04-05
IL263121A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
EA201892745A1 (ru) Фосфорамидатные производные нуклеозида в качестве противораковых агентов
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
CY1122074T1 (el) Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις
MX391981B (es) Derivados de benzooxazol como inmunomoduladores.
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
MX386680B (es) Polimorfo de macrociclo de diarilo.
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12018500263A1 (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201692422A1 (ru) Состав, содержащий пролекарство гемцитабина
EA201892769A3 (ru) Сложные диэфиры ациклических нуклеозидфосфонатов
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
MX373324B (es) Compuestos piridínicos de pladienolida y métodos de uso.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201990400A1 (ru) Соединения и композиции и их применение
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX380677B (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
EA202190058A1 (ru) Композиции фосфорамидатных производных нуклеозидных лекарственных средств